JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pugh, G.
Right arrow Articles by Welch, S. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pugh, G., Jr.
Right arrow Articles by Welch, S. P.

Vol. 281, Issue 2, 730-737, 1997

Involvement of Dynorphin B in the Antinociceptive Effects of the Cannabinoid CP55,940 in the Spinal Cord1

George Pugh, Jr., David J. Mason, Jr., Vera Combs and Sandra P. Welch

Department of Pharmacology and Toxicology, Medical College of Virginia/Virginia Commonwealth University, Richmond, Virginia

Intrathecal administration of Delta 9-tetrahydrocannabinol (Delta 9-THC) but not the cannabinoid agonist CP55,940 enhances the antinociception produced by morphine. In addition, CP55,940- and Delta 9-THC-induced antinociception is blocked by the kappa opioid antagonist norbinaltorphimine, and both cannabinoids are cross-tolerant to kappa agonists but do not act directly at the kappa receptor. Previous work in our laboratory has implicated dynorphins in the antinociceptive effects of Delta 9-THC and its enhancement of morphine-induced antinociception. The goal of the present study was to evaluate the role of dynorphins in the antinociceptive effects of CP55,940 at the spinal level. Pretreatment of mice with antisera to dynorphin A(1-17), dynorphin A(1-8) or alpha -neoendorphin, all of which have been shown to retain specificity for blockade of their respective peptide in vivo, blocked the antinociceptive effects of Delta 9-THC but not CP55,940. Dynorphin B produced antinociceptive effects on intrathecal administration to mice. Like CP55,940, dynorphin B failed to enhance the antinociceptive effects of morphine, whereas dynorphin A(1-17) and alpha -neoendorphin enhanced the antinociceptive effects of morphine. Using spinal catheterization of the rat, CP55,940 administration was shown to produce a significant release of dynorphin B concurrent with the production of antinociception. Our data suggest that CP55,940 induces a release of spinal dynorphin B that contributes at least in part to its antinociceptive effects in the spinal cord.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
P. Pacher, S. Batkai, and G. Kunos
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
A. Zimmer, E. Valjent, M. Konig, A. M. Zimmer, P. Robledo, H. Hahn, O. Valverde, and R. Maldonado
Absence of Delta -9-Tetrahydrocannabinol Dysphoric Effects in Dynorphin-Deficient Mice
J. Neurosci., December 1, 2001; 21(23): 9499 - 9505.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
M. Navarro, M. R. A. Carrera, W. Fratta, O. Valverde, G. Cossu, L. Fattore, J. A. Chowen, R. Gomez, I. del Arco, M. A. Villanua, et al.
Functional Interaction between Opioid and Cannabinoid Receptors in Drug Self-Administration
J. Neurosci., July 15, 2001; 21(14): 5344 - 5350.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
O. Valverde, R. Maldonado, E. Valjent, A. M. Zimmer, and A. Zimmer
Cannabinoid Withdrawal Syndrome Is Reduced in Pre-Proenkephalin Knock-Out Mice
J. Neurosci., December 15, 2000; 20(24): 9284 - 9289.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
P. Sharpe and G. Smith
Cannabis: Time for Scientific Evaluation of This Ancient Remedy?
Anesth. Analg., February 1, 2000; 90(2): 237 - 237.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. P. Welch, J. W. Huffman, and J. Lowe
Differential Blockade of the Antinociceptive Effects of Centrally Administered Cannabinoids by SR141716A
J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1301 - 1308.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. A. Vivian, S. Kishioka, E. R. Butelman, J. Broadbear, K. O. Lee, and J. H. Woods
Analgesic, Respiratory and Heart Rate Effects of Cannabinoid and Opioid Agonists in Rhesus Monkeys: Antagonist Effects of SR 141716A
J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 697 - 703.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.